Novel Treatment Options for Multiple Myeloma

医学 达拉图穆马 嵌合抗原受体 肿瘤科 临床试验 多发性骨髓瘤 内科学 免疫疗法 重症监护医学 来那度胺 癌症
作者
Andrew J. Portuguese,Rahul Banerjee,Gui Zhen Chen,Swetha Reddi,Andrew J. Cowan
出处
期刊:JCO oncology practice [Lippincott Williams & Wilkins]
卷期号:21 (7): 950-961 被引量:5
标识
DOI:10.1200/op-24-00752
摘要

Multiple myeloma (MM), the second most common hematologic malignancy in the United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line of therapy. Despite the virtually incurable nature of MM, recent therapeutic breakthroughs have fundamentally reshaped its treatment landscape. This review explores evolving care paradigms, spanning from newly diagnosed MM to relapsed or refractory disease. In the frontline setting, treatment strategies have shifted beyond their traditional emphasis on autologous stem-cell transplant eligibility to a broader categorization of patients on the basis of their suitability for quadruplet therapy. In the relapsed/refractory setting, novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, have revolutionized treatment, offering new hope for patients with previously limited options. Precision medicine is playing a growing role in MM treatment, with venetoclax showing significant efficacy in patients with t(11;14) translocation, advancing targeted therapy for this subgroup. On the horizon, investigational CAR-T products and cereblon E3 ligase modulators, such as mezigdomide and iberdomide, may provide faster, more durable responses compared with current therapies. In addition, belantamab mafodotin, an antibody-drug conjugate withdrawn from the US market in 2022, is on the verge of reapproval after positive results from recent randomized trials. While these therapies offer significant potential, challenges remain in managing toxicity, ensuring treatment accessibility, and optimizing sequencing strategies. As the therapeutic arsenal expands, the need for personalized MM treatment plans that balance efficacy with quality of life becomes even more essential.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shuyiWang发布了新的文献求助10
刚刚
Susuna完成签到 ,获得积分10
1秒前
木头发布了新的文献求助10
1秒前
2秒前
3秒前
时尚的紫蓝完成签到,获得积分10
4秒前
4秒前
yhr发布了新的文献求助10
5秒前
哭泣的凝芙完成签到,获得积分10
5秒前
6秒前
6秒前
geejee完成签到,获得积分10
6秒前
李健的小迷弟的应助被木头采纳,获得10
6秒前
7秒前
研友_ZeoKYL完成签到,获得积分10
7秒前
漫漫驳回了Jasper的应助
7秒前
suzy发布了新的文献求助10
8秒前
wangxiaomin发布了新的文献求助10
9秒前
10秒前
10秒前
卡卡完成签到 ,获得积分10
10秒前
XPR发布了新的文献求助10
10秒前
Owen的应助被CMC智能助手采纳,获得10
10秒前
11秒前
11秒前
只争朝夕的应助被cz采纳,获得10
12秒前
十七发布了新的文献求助10
12秒前
13秒前
星星完成签到,获得积分10
13秒前
SunH完成签到,获得积分10
13秒前
follower8107完成签到,获得积分10
14秒前
14秒前
15秒前
SunH发布了新的文献求助10
15秒前
16秒前
烧饼拌糖完成签到,获得积分10
16秒前
魔芋小心发布了新的文献求助10
16秒前
ldxghh发布了新的文献求助10
16秒前
一周八颗蛋完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621